Eli Lilly Expands Zepbound Offerings, Lowers Prices for Self-Pay Patients

INDIANAPOLIS, Feb. 25, 2025 – Eli Lilly and Company (NYSE: LLY) has introduced 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, priced at $499 through the new Zepbound Self Pay Journey Program. The company also reduced the cost of 2.5 mg and 5 mg vials.

Available exclusively via LillyDirect Self Pay Pharmacy Solutions, this initiative bypasses third-party entities to offer transparent pricing. The Obesity Action Coalition praised the move but emphasized the need for broader healthcare coverage.

Lilly lowered the 2.5 mg vial to $349 per month and 5 mg to $499, while the 7.5 mg ($599) and 10 mg ($699) vials now cost $499 if refilled within 45 days.

Lilly’s Patrik Jonsson reiterated the company’s commitment to making obesity treatment more affordable while advocating for improved insurance coverage.

Commenti

Post popolari in questo blog

Curious drug names and their origin

Pharma Quiz 3

Pokemon or Medicine